Meridian Bioscience Inc. (VIVO) News

Meridian Bioscience Inc. (VIVO): $20.50

-0.18 (-0.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter VIVO News Items

VIVO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VIVO News Highlights

  • 500 - Internal server error
  • Over the past 14 days, the trend for VIVO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about VIVO are AHPI, ARDS and DTSS.

Latest VIVO News From Around the Web

Below are the latest news stories about Meridian Bioscience Inc that investors may wish to consider to help them evaluate VIVO as an investment opportunity.

Global Rapid Medical Diagnostics Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Abbot Laboratories, Thermo Fisher Scientific Inc., AccuBioTech Co. Ltd., Bio-Rad Laboratories, OraSure Technologies Inc., AccessBio Inc., Trinity Biotech, Meridian Bioscience Inc., Quidel Corporation, BD

The report on Global Rapid Medical Diagnostics Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []

Jumbo News | July 23, 2021

Meridian To Buy Urea Breath Test For H. Pylori From Otsuka America Pharmaceutical For $20M

Meridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash. The transaction will close in Meridian's fiscal fourth quarter, which ends in September. With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test to detect Helicobacter pylori. Meridian expects the acquisition to add more than $20 million of annual revenue, enhancin

Yahoo | July 23, 2021

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationships in North America to su

Yahoo | July 23, 2021

Investors Shouldn't Overlook The Favourable Returns On Capital At Meridian Bioscience (NASDAQ:VIVO)

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...

Yahoo | July 21, 2021

Meridian Bioscience to Hold Third Quarter Fiscal 2021 Financial Results Conference Call on August 6, 2021

CINCINNATI, July 14, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021.

Intrado Digital Media | July 14, 2021

XELA, SOHU, SEED among mid-day movers.

 Gainers: Red Cat Holdings (RCAT) +97%.Allied Healthcare Products (AHPI) +82%.Orbsat (OSAT) +45%.Exela Technolcorp (HBMD) +28%.Integrated Media Technology (IMTE) +22%.Sohu.com (SOHU) +21%.Losers: MediaCo (MDIA) -45%.SGOCO Group (SGOC) -46%.Mer Telemanagement Solutions (MTSL) -25%.Datasea (DTSS) -22%.Gatos Silver (GATO) -19%.Aridis Pharmaceuticals (ARDS) -17%.Origin Agritech (SEED) -17%.Takung Art (TKAT) -17%.Xtant Medical (XTNT) -16%....

Seeking Alpha | July 13, 2021

Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter

CINCINNATI, July 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. Preliminary unaudited revenue for the third quarter of fiscal 2021 is expected to be approximately $63.5 million, below expectations. The Diagnostics segment performance was impacted negatively by recent supply chain issues with our LeadCare reagents that

Yahoo | July 13, 2021

Isothermal Nucleic Acid Amplification Market Set to Grow with Massive CAGR by 2028. Major Players PreAnalytiX, Meridian Bioscience, Eiken Chemical, Lucigen, OptiGene, etc.

Industry Growth Insights (IGI) announces the release of a new report, Isothermal Nucleic Acid Amplification Market Research Report 2021. The statistics and insights provide an in-depth look into the market and opportunities. The report provides a comprehensive analysis of key market shares, size, trends, and forecasts for the global Isothermal Nucleic Acid Amplification market. It []

Tramways Monthly | July 12, 2021

Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Meridian Bioscience (VIVO) closed at $22.05, marking a +1.61% move from the previous day.

Yahoo | July 9, 2021

Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

CINCINNATI, June 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. On February 22, 2021, Meridian voluntarily withdrew its EUA application in order to conduct additional studies ba

Yahoo | June 28, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7155 seconds.